JANUARY 29, 2013 – Axinn announced that Russell Steinthal, a member of the firm’s antitrust group, has been promoted to the position of partner. The firm also announced that Josephine Liu and Jason Murata, members of the firm’s intellectual property group, have been promoted to the position of counsel.
“We congratulate Russell, Josephine and Jason for their accomplishments; all three have made tremendous contributions to the firm,” said Managing Partner James Veltrop. “With rising talent in the antitrust and intellectual property practices, Axinn is poised to build on the firm’s reputation as a leader in these areas.”
Mr. Steinthal, who works from Axinn’s New York office, is a partner in the firm’s antitrust group and has experience with the full range of the group’s practice, including litigation, mergers and acquisitions, and corporate counseling. Mr. Steinthal has served as the lead antitrust attorney on a number of significant matters, and as a key in diverse industries including chemicals, packaging, retail, telecommunications and, most recently, several major patent acquisitions. He regularly counsels clients on a range of merger-related issues, including premerger notification requirements under the Hart-Scott-Rodino Act, the antitrust implications of merger agreement covenants and the regulatory review process, as well as non-merger issues.
Dr. Liu, who also works from Axinn’s New York office, is a member of the firm’s intellectual property group. She represents and counsels clients in the pharmaceutical, biotechnology and animal health industries. Dr. Liu regularly litigates cases brought under Section 505(j) of the Federal Food, Drug and Cosmetic Act (Hatch-Waxman). Her experience also includes representing clients in the medical device and petroleum products industries on various matters, including products liability and environmental liability.
Mr. Murata, who works from Axinn’s Hartford office, is a member of the firm’s intellectual property group. His practice focuses primarily on patent and trade secret litigation, with an emphasis in the mechanical, chemical and pharmaceutical arts, including patent litigation and consultation arising under Section 505(j) of the Federal Food, Drug and Cosmetic Act.